Article
Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.
Science China. Life sciences - 1 Apr 2020
Wang Yongbo, Bao Yufang, Zhang Sirui, Wang Zefeng
Abstract excerpt
RNA splicing dysregulation is widespread in cancer. Accumulating evidence demonstrates that splicing defects resulting from splicing dysregulation play critical roles in cancer pathogenesis and can serve as new biomarkers and therapeutic targets for cancer intervention. These findings have greatly deepened the mechanistic understandings of the regulation of alternative splicing in cancer cells, leading to rapidly...
Topics
- Animals
- Antineoplastic Agents
- Base Sequence
- Biocatalysis
- Catalytic Domain
- Cell Line, Tumor
- Gene Expression Regulation, Neoplastic
- Genetic Therapy
- Humans
- Mutation
- Neoplasms